Selexipag: A Review in Pulmonary Arterial Hypertension

Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment

(2016) Priska Kaufmann et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects

(2016) Shirin Bruderer et al.   CLINICAL THERAPEUTICS

Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension

(2016) Caroline O’Connell et al.   DRUG SAFETY

Medical therapies for pulmonary arterial hypertension

(2016) Tomas Pulido et al.   HEART FAILURE REVIEWS

Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study

(2016) V.F. Tapson et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

(2015) Priska Kaufmann et al.   American Journal of Cardiovascular Drugs

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

(2015) Priska Kaufmann et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

(2015) Nazzareno Galiè et al.   EUROPEAN HEART JOURNAL

Selexipag for the Treatment of Pulmonary Arterial Hypertension

(2015) Olivier Sitbon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?

(2015) Boris I. Medarov et al.   RESPIRATORY MEDICINE

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

(2014) Darren B. Taichman et al.   CHEST

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

(2014) Shirin Bruderer et al.   PHARMACOLOGY

Definitions and Diagnosis of Pulmonary Hypertension

(2013) Marius M. Hoeper et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

(2012) Gérald Simonneau et al.   EUROPEAN RESPIRATORY JOURNAL

Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs

(2011) Zeenat Safdar   RESPIRATORY MEDICINE

Selexipag: A Selective Prostacyclin Receptor Agonist that Does Not Affect Rat Gastric Function

(2010) K. Morrison et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2- -N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form,  acetic Acid (MRE-269), on Rat Pulmonary Artery

(2008) K. Kuwano et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS